These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38915518)

  • 1. Stat3-mediated Atg7 expression enhances anti-tumor immunity in melanoma.
    Zimmerman SM; Suh E; Smith SR; Souroullas GP
    bioRxiv; 2024 Jun; ():. PubMed ID: 38915518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ezh2
    Zimmerman SM; Nixon SJ; Chen PY; Raj L; Smith SR; Paolini RL; Lin PN; Souroullas GP
    Oncogene; 2022 Nov; 41(46):4983-4993. PubMed ID: 36220978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.
    Souroullas GP; Jeck WR; Parker JS; Simon JM; Liu JY; Paulk J; Xiong J; Clark KS; Fedoriw Y; Qi J; Burd CE; Bradner JE; Sharpless NE
    Nat Med; 2016 Jun; 22(6):632-40. PubMed ID: 27135738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EZH2: an emerging role in melanoma biology and strategies for targeted therapy.
    Tiffen J; Gallagher SJ; Hersey P
    Pigment Cell Melanoma Res; 2015 Jan; 28(1):21-30. PubMed ID: 24912396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.
    Christofides A; Karantanos T; Bardhan K; Boussiotis VA
    Oncotarget; 2016 Dec; 7(51):85624-85640. PubMed ID: 27793053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential.
    Gan L; Yang Y; Li Q; Feng Y; Liu T; Guo W
    Biomark Res; 2018; 6():10. PubMed ID: 29556394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EZH2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibition.
    Romero P; Richart L; Aflaki S; Petitalot A; Burton M; Michaud A; Masliah-Planchon J; Kuhnowski F; Le Cam S; Baliñas-Gavira C; Méaudre C; Luscan A; Hamza A; Legoix P; Vincent-Salomon A; Wassef M; Holoch D; Margueron R
    Nat Commun; 2024 Apr; 15(1):3452. PubMed ID: 38658543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lonicerin targets EZH2 to alleviate ulcerative colitis by autophagy-mediated NLRP3 inflammasome inactivation.
    Lv Q; Xing Y; Liu J; Dong D; Liu Y; Qiao H; Zhang Y; Hu L
    Acta Pharm Sin B; 2021 Sep; 11(9):2880-2899. PubMed ID: 34589402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flow-dependent epigenetic regulation of IGFBP5 expression by H3K27me3 contributes to endothelial anti-inflammatory effects.
    Xu S; Xu Y; Yin M; Zhang S; Liu P; Koroleva M; Si S; Little PJ; Pelisek J; Jin ZG
    Theranostics; 2018; 8(11):3007-3021. PubMed ID: 29896299
    [No Abstract]   [Full Text] [Related]  

  • 10. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.
    Chu L; Tan D; Zhu M; Qu Y; Ma X; Song BL; Qi W
    J Biol Chem; 2023 Apr; 299(4):103073. PubMed ID: 36858198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atg7 Overcomes Senescence and Promotes Growth of BrafV600E-Driven Melanoma.
    Xie X; Koh JY; Price S; White E; Mehnert JM
    Cancer Discov; 2015 Apr; 5(4):410-23. PubMed ID: 25673642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging Roles of LncRNAs in the EZH2-regulated Oncogenic Network.
    Hao A; Wang Y; Stovall DB; Wang Y; Sui G
    Int J Biol Sci; 2021; 17(13):3268-3280. PubMed ID: 34512145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-canonical functions of EZH2 in cancer.
    Zimmerman SM; Lin PN; Souroullas GP
    Front Oncol; 2023; 13():1233953. PubMed ID: 37664059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth.
    Barsotti AM; Ryskin M; Zhong W; Zhang WG; Giannakou A; Loreth C; Diesl V; Follettie M; Golas J; Lee M; Nichols T; Fan C; Li G; Dann S; Fantin VR; Arndt K; Verhelle D; Rollins RA
    Oncotarget; 2015 Feb; 6(5):2928-38. PubMed ID: 25671303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NF-YA promotes invasion and angiogenesis by upregulating EZH2-STAT3 signaling in human melanoma cells.
    Xu Z; Sun Y; Guo Y; Qin G; Mu S; Fan R; Wang B; Gao W; Wu H; Wang G; Zhang Z
    Oncol Rep; 2016 Jun; 35(6):3630-8. PubMed ID: 27109360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromatin regulator PRC2 is a key regulator of epigenetic plasticity in glioblastoma.
    Natsume A; Ito M; Katsushima K; Ohka F; Hatanaka A; Shinjo K; Sato S; Takahashi S; Ishikawa Y; Takeuchi I; Shimogawa H; Uesugi M; Okano H; Kim SU; Wakabayashi T; Issa JP; Sekido Y; Kondo Y
    Cancer Res; 2013 Jul; 73(14):4559-70. PubMed ID: 23720055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes.
    Tiffen JC; Gunatilake D; Gallagher SJ; Gowrishankar K; Heinemann A; Cullinane C; Dutton-Regester K; Pupo GM; Strbenac D; Yang JY; Madore J; Mann GJ; Hayward NK; McArthur GA; Filipp FV; Hersey P
    Oncotarget; 2015 Sep; 6(29):27023-36. PubMed ID: 26304929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of EZH2 histone methyltrasferase in melanoma progression and metastasis.
    Mahmoud F; Shields B; Makhoul I; Hutchins LF; Shalin SC; Tackett AJ
    Cancer Biol Ther; 2016 Jun; 17(6):579-91. PubMed ID: 27105109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of catalytic and non-catalytic activity inhibitors against PRC2-EZH2 complex through multiple high-throughput screening campaigns.
    Zhou Y; Du DH; Wang J; Cai XQ; Deng AX; Nosjean O; Boutin JA; Renard P; Yang DH; Luo C; Wang MW
    Chem Biol Drug Des; 2020 Oct; 96(4):1024-1051. PubMed ID: 32394628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein kinase A-mediated phosphorylation regulates STAT3 activation and oncogenic EZH2 activity.
    Özeş AR; Pulliam N; Ertosun MG; Yılmaz Ö; Tang J; Çopuroğlu E; Matei D; Özeş ON; Nephew KP
    Oncogene; 2018 Jun; 37(26):3589-3600. PubMed ID: 29576612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.